Payment overview · 2025
General Payments
$770.19
42 reported records · 18 companies
Healthcare provider profile · identity verified
Michelle Cass, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BLUE SPRINGS, MO · NPI 1164907622
Verified facts
What the public records show
CMS Open Payments records show Michelle Cass, APRN received $770.19 in general payments during 2025 across 42 reported records.
PFIZER INC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rexulti, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.70 | 18.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.82 | 13.6% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.21 | 12.4% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $78.72 | 10.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.75 | 6.8% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $39.59 | 5.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.55 | 5.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.02 | 4.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.46 | 3.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.36 | 2.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.32 | 2.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.65 | 2.7% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.24 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.66 | 2.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $16.77 | 2.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.58 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.63 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.16 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $770.19 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $101.50 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.65 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $85.18 | 8 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $78.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.60 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.46 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 65 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 176 | 61 |
| Lisinopril | Lisinopril | 141 | 52 |
| Losartan Potassium | Losartan Potassium | 127 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 44 |
| Methylprednisolone | Methylprednisolone | 112 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 52 |
| Gabapentin | Gabapentin | 105 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 37 |
| Ozempic | Semaglutide | 93 | 26 |
| Prednisone | Prednisone | 87 | 53 |
| Omeprazole | Omeprazole | 86 | 31 |
| Sertraline Hcl | Sertraline Hcl | 81 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 42 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 74 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 24 |
| Tramadol Hcl | Tramadol Hcl | 69 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 20 |
| Mounjaro | Tirzepatide | 65 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 37 |
| Montelukast Sodium | Montelukast Sodium | 64 | 21 |
| Meloxicam | Meloxicam | 61 | 27 |
| Potassium Chloride | Potassium Chloride | 61 | 21 |
| Metformin Hcl | Metformin Hcl | 60 | 22 |
| Pregabalin | Pregabalin | 59 | 12 |
| Jardiance | Empagliflozin | 58 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 12 |
| Carvedilol | Carvedilol | 55 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 44 |
| Simvastatin | Simvastatin | 48 | 15 |
| Alendronate Sodium | Alendronate Sodium | 47 | 19 |
| Furosemide | Furosemide | 47 | 20 |
| Valacyclovir | Valacyclovir Hcl | 42 | 15 |
| Ketoconazole | Ketoconazole | 39 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Alprazolam | Alprazolam | 34 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 31 |
| Buspirone Hcl | Buspirone Hcl | 32 | 14 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 13 |
| Eliquis | Apixaban | 30 | suppressed |
| Estradiol | Estradiol | 30 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | 11 |
| Atenolol | Atenolol | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Wegovy | Semaglutide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | 13 |
| Glimepiride | Glimepiride | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $770.19 · 42 records | PFIZER INC. | ABRYSVO, AIRSUPRA, APRETUDE, Auvelity, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, LEQVIO, MOUNJARO, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, STRENSIQ, TONMYA, UBRELVY, VAXNEUVANCE, VRAYLAR, WATCHMAN FLX, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error